Leaving FDA, Califf warns of trouble ahead

In an interview, the outgoing commissioner was wary of Trump administration but unapologetic about controversial decisions during his term.

January 8, 2025 Check out STAT+

Sponsored By

Photo illustration/STAT, Drew Angerer/Getty Images STAT+ | Leaving FDA, Califf is unapologetic — and warns of staff departures In an interview, the outgoing commissioner of the agency was wary of Trump administration but unapologetic about controversial decisions during his term. By Matthew Herper STAT+ | Transcarent to acquire Accolade for $621 million creating benefits tech giant Transcarent on Wednesday said it was buying Accolade, a health benefits company, for $621 million, offering a significant premium on Accolade's share price. By Mario Aguilar Opinion: WHO director-general: Jimmy Carter's legacy can guide us through turbulent times Tedros Adhanom Ghebreyesus, WHO director-general, says the former president's work continues to protect millions from disease and war. By Tedros Adhanom Ghebreyesus Alex Hogan/STAT STAT+ | With a major patent cliff coming, will JPM play host to some serious deal-making? Drugmakers stand to lose $400 billion in revenue as patents expire for Keytruda, Eliquis, and other blockbusters. That could spur deals at JPM 2025. By Allison DeAngelis and Adam Feuerstein STAT+ | Scribe Therapeutics becomes latest CRISPR company to announce layoffs  Co-founded by Jennifer Doudna, Scribe will lose 20% of its staff as it moves toward clinical trials with its CasX gene editor. By Jason Mast STAT+ | Opinion: Most cancers have no screening test. Let's change that What if the lack of a government mandate for insurance coverage is the real reason there's no screening test for ovarian cancer? By Dawn Mattoon Daniele Emedoli/San Raffaele Hospital Q&A: How electrical stimulation can improve rehabilitation after spinal cord injury A new study found that high-frequency stimulation reduced spasticity, and improved patients' ability to walk after spinal cord injury. By Timmy Broderick STAT+ | Galapagos to split itself into two companies as part of turnaround plan The Galapagos branch will prioritize work in cancer cell therapies, while the spin-out arm aims to build a pipeline through transactions. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser